PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024
By Dr. Matthew Watson
SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
See the original post here:
PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024
Related Post
- Tr1X to Participate at Upcoming Healthcare Investment Conferences - September 14th, 2024
- Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024 - September 14th, 2024
- Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines - September 14th, 2024
- CorMedix Inc. to Present at the Cantor Global Healthcare Conference - September 14th, 2024
- RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress - September 14th, 2024
- Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series - September 14th, 2024
- C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial... - September 14th, 2024
- Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial - September 14th, 2024
- Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th - September 14th, 2024
- Virbac 2024 half-year results - September 14th, 2024
- Virbac: Information on the departure of Sébastien Huron - September 14th, 2024
- Virbac : the board of directors announces a capital reduction through cancellation of treasury shares - September 14th, 2024
- Virbac : Public release of the Half-Year Financial Report at 30 June 2024. - September 14th, 2024
- Virbac : Half-yearly financial report 2024 - September 14th, 2024
- Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - September 14th, 2024
- Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq - September 14th, 2024
- Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc. - September 14th, 2024
- Company Statement on FDA Advisory Committee Meeting - September 14th, 2024
- iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of... - September 14th, 2024
- IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer - September 14th, 2024
- Total number of shares and voting rights in Zealand Pharma on August 30, 2024 - September 3rd, 2024
- IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with... - September 3rd, 2024
- Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update - September 3rd, 2024
- Receipt of Nasdaq Delisting Determination - Plans to Appeal - September 3rd, 2024
- Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop... - September 3rd, 2024
- Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates - September 3rd, 2024
- George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC... - September 3rd, 2024
- Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer - September 3rd, 2024
- Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 - September 3rd, 2024
- Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in... - September 3rd, 2024
- PCI Biotech: Employee share option scheme - September 3rd, 2024
- Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK - September 3rd, 2024
- Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today - September 3rd, 2024
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 3rd, 2024
- Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and... - September 3rd, 2024
- Amended terms of Idorsia’s 2024 convertible bonds become effective - September 3rd, 2024
- Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine... - September 3rd, 2024
- CARBIOS appoints Tommy Maussin as Chief Marketing Officer and Executive Committee member to develop CARBIOS’ presence with brands worldwide - September 3rd, 2024
- Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate - September 3rd, 2024
- QIAGEN N.V. launches non-US offering of net share settled convertible bonds - September 3rd, 2024
- Structure Therapeutics Announces Participation in Upcoming Investor Conferences - August 27th, 2024
- Notable Labs Announces CEO Transition - August 27th, 2024
- Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference - August 27th, 2024
- Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer - August 27th, 2024
- IO Biotech Announces Participation in Upcoming Investor Conferences - August 27th, 2024
- Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1) - August 27th, 2024
- Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors - August 27th, 2024
- BioSyent Declares Third Quarter 2024 Dividend - August 27th, 2024
- Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors - August 27th, 2024
- BioSyent Releases Financial Results for Q2 and H1 2024 - August 27th, 2024
- Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference - August 27th, 2024
- Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L. - August 27th, 2024
- Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update - August 27th, 2024
- Telix Announces Reorganisation to Deliver on Strategic Priorities - August 27th, 2024
- ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics - August 27th, 2024
- Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration - August 27th, 2024
- Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH - August 27th, 2024
- European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers... - August 27th, 2024
- Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy - August 27th, 2024
- Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Singapore - August 27th, 2024
- Certara Launches Phoenix™ Version 8.5 Drug Development Software - August 19th, 2024
- Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 - August 19th, 2024
- Aptose Announces Adjournment of its Special Meeting of Shareholders - August 19th, 2024
- Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents - August 19th, 2024
- Vistin Pharma ASA: Invitation to Q2 2024 conference call - August 19th, 2024
- Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age - August 19th, 2024
- Tonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares... - August 19th, 2024
- AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update - August 19th, 2024
- Cannara Biotech Achieves its Highest National Market Share of 3.2% in July 2024 and Announces Investor Webcast Scheduled for August 20, 2024 - August 19th, 2024
- Genmab Announces Changes to its Executive Committee - August 19th, 2024
- Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances - August 19th, 2024
- Zealand Pharma major shareholder announcement: Bank of America Corporation - August 19th, 2024
- Theriva Biologics Announces Reverse Stock Split - August 19th, 2024
- Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental... - August 19th, 2024
- ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics - August 19th, 2024
- SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million - August 19th, 2024
- Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards - August 19th, 2024
- Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global Stakeholders - August 19th, 2024
- BioSenic S.A.: Transparency notification received from ABO Infinium Americas OpCo LTD. - August 19th, 2024
- Burning Rock Biotech Limited Announces Expected Delisting of American Depositary Shares - August 19th, 2024
Global News Feed
Comments Off on PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024 |
July 16th, 2024
This author published 5772 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research